ArticleACS omega2025
Evaluation of the Therapeutic Efficacy of the Newly Formulated Drug "Novostron" as an Experimental Basis for Clinical Trials.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic wound infections driven by multidrug-resistant (MDR) bacteria continue to challenge modern medicine. This study introduces "Novostron", an innovative topical iodine-based formulation incorporating dextrin and metal halides designed to overcome the limitations of existing antiseptics, such as volatility and cytotoxicity. The complex's physicochemical properties were analyzed using infrared (IR) and ultraviolet (UV) spectroscopy, alongside thermogravimetric analysis, confirming its stability and robust iodine retention. Stability assessments revealed minimal iodine loss under optimal refrigerated conditions. In a rat skin wound model, the microbial load was significantly reduced to 1.4 ± 0.5 CFU/cm
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.